Other Vaccines - Italy

Italy

Highlights

The revenue in the Other Vaccines market in Italy is forecasted to reach US$798.90m in 2024.
It is expected to demonstrate an annual growth rate (CAGR 2024-2029) of 9.70%, leading to a market volume of US$1.27bn by 2029.
When compared globally, United States is projected to generate the highest revenue, amounting to US$24.73bn in 2024.
Italy's pharmaceutical industry is experiencing a surge in the development and production of other vaccines, fueling the country's efforts to improve public health and combat infectious diseases.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

Italy, known for its picturesque landscapes, rich history and culture, and delicious cuisine, also has a thriving pharmaceutical industry. The Other Vaccines market in Italy has seen significant growth in recent years, driven by various factors.

Customer preferences: Italian consumers are becoming increasingly health-conscious, which has led to a rise in demand for preventative healthcare measures such as vaccines. Furthermore, the aging population in Italy has created a greater need for vaccines to prevent illnesses that are more prevalent in older individuals.

Trends in the market: One of the key trends in the Other Vaccines market in Italy is the increasing adoption of combination vaccines. Combination vaccines offer multiple vaccinations in a single shot, which is more convenient for patients and can help to improve vaccination rates. Additionally, there has been a growing focus on developing vaccines for diseases that were previously considered rare or neglected, such as meningitis B and C.

Local special circumstances: Italy has a national healthcare system that provides universal coverage for its citizens. This means that vaccines are generally accessible to all individuals, regardless of their income level. Additionally, the Italian government has implemented various vaccination campaigns to increase awareness and uptake of vaccines, particularly among vulnerable populations such as children and the elderly.

Underlying macroeconomic factors: The Italian pharmaceutical industry is a significant contributor to the country's economy, with a large number of pharmaceutical companies operating in Italy. This has created a favorable environment for the development and distribution of vaccines. However, the industry is also subject to various regulatory and pricing pressures, which can impact the profitability of companies operating in the market. Additionally, the ongoing COVID-19 pandemic has highlighted the importance of vaccines and may lead to increased investment in vaccine development and distribution in the future.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.